Physician profile
Fady T Charbel
NPI 1700899721
$507,279.26
in general payments reported to CMS, 2019-2025
10 companies · $41K in 2025
The $41K reported for 2025 was more than what 94% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78K · 2020: $56K · 2021: $81K · 2022: $88K · 2023: $86K · 2024: $77K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $102K · Travel and Lodging: $67K · Consulting Fee: $33K · Food and Beverage: $1,688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $101,696.01 |
| Travel and Lodging | $66,939.67 |
| Consulting Fee | $33,483.00 |
| Food and Beverage | $1,688.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Transonic Systems INC. | $412,891.77 | 2019-2025 | |
| Aesculap, INC. | $71,430.34 | 2019-2025 | Aesculap, None, No Applicable Marketed Product Name |
| Stryker Corporation | $19,983.16 | 2019-2024 | Duramatrix, Adherus Autospray Dural Sealant |
| Aesculap Ag | $1,669.60 | 2020 | |
| Zimmer Biomet Holdings, INC. | $652.91 | 2021-2025 | Neuro Plating System, Neuro Plating System |
| Medtronic USA, INC. | $334.76 | 2019 | |
| Silk Road Medical, INC. | $153.08 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Carl Zeiss Meditec, INC. | $94.67 | 2019 | |
| Mizuho America, INC. | $34.50 | 2021 | |
| Clearpoint Neuro, INC. | $34.47 | 2023 | Clearpoint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$15,664.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fady Charbel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.